App-Quantinova.ai

Secukinumab provides rapid and sustained resolution of enthesitis in psoriatic arthritis patients: pooled analysis of two Phase 3 studies, FUTURE 2 and FUTURE 3

Laura C Coates - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

secukinumab

Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 4-year results from the Phase 3 FUTURE 2 study

Iain B McInnes - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriatic arthritis

Methotrexate

Secukinumab demonstrates a consistent safety profile with up to 5 years’ treatment in patients with psoriatic arthritis and moderate-to-severe plaque psoriasis: updated pooled safety analyses

Iain B McInnes - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriatic arthritis

secukinumab

Secukinumab provides sustained improvements in the signs and symptoms in psoriatic arthritis: final 5-year efficacy and safety results from the FUTURE 1 Phase 3 trial

Hasan Tahir - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriatic arthritis

secukinumab

Changing trends in TNF inhibitor prescribing for axial spondyloarthritis: the influence of National Institute for Health and Care Excellence guidance

Kit Yee Wong - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

TA-383

Low incidence of both new-onset and flares of uveitis in secukinumab-treated patients with ankylosing spondylitis: clinical trial and post-marketing safety analysis

Helena Marzo-Ortega - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Ophthalmology (OP)

Ankylosing spondylitis

secukinumab

Secukinumab 150 mg provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 4-year results from the Phase 3 trial, MEASURE 2

Helena Marzo-Ortega - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Ankylosing spondylitis

secukinumab

Secukinumab demonstrates rapid and sustained efficacy in ankylosing spondylitis patients with normal or elevated baseline C-reactive protein levels: pooled analysis of two Phase 3 studies

Nick Barkham - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Ankylosing spondylitis

secukinumab

Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in patients with psoriatic arthritis and ankylosing spondylitis during a 52week treatment period

Iain B McInnes - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ankylosing spondylitis

secukinumab

Secukinumab demonstrates low radiographic progression and sustained efficacy through 4 years in patients with active ankylosing spondylitis

Paul Emery - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Ankylosing spondylitis

secukinumab

Chiropractic and osteopathic knowledge and experience in treating patients with axial spondyloarthritis

Cee Yi Yong - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

Patient health questionnaire-4 screening and its composite domains indicate high levels of anxiety and depression in patients with psoriatic arthritis and are not predicted by other patient factors

Alistair Tindell - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Psoriatic arthritis

N/A

Improving standards of care of axial spondyloarthritis through implementation of NICE Quality standards 170 across the South Coast Axial Spondyloarthritis Network

Antoni Chan - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

Adherence to web-based physiotherapy in people with axial spondyloarthritis

Lorna Paul - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

In axial spondyloarthritis, magnitude of improved disease activity after six months of biologic disease-modifying treatment may be more relevant to short-term functional outcome than achieving an inactive disease state

Thomas Williams - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

Real life experience of tocilizumab for Takayasu arteritis

Kavina Shah - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Takayasu arteritis

Tocilizumab

Interleukin-1β expressing inflammatory macrophages in temporal arteries affected by giant cell arteritis

Gary Reynolds - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Giant cell arteritis

Collagenase

Acute phase reactant levels and prednisone doses at disease flare in patients with giant cell arteritis: prospective data from the GiACTA trial

John H Stone - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Giant cell arteritis

Prednisone

A study to evaluate the factors most predictive of a positive temporal artery biopsy in giant cell arteritis

Ameen Jubber - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Giant cell arteritis

N/A

Paul Bacon award: rheumatology-led fast track pathways for giant cell arteritis improve the security of the diagnosis and reduce the need for temporal artery biopsy

Vanessa Quick - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Giant cell arteritis

Prednisolone

Filters

45280 Abstracts